Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Drug: Mobocertinib for EGFR Exon 20 insertion NSCLC - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Drug: Mobocertinib for EGFR Exon 20 insertion NSCLC

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Drug: Mobocertinib for EGFR Exon 20 insertion NSCLC

New Drug: Mobocertinib for EGFR Exon 20 insertion NSCLC
Study:
  • Open-label Phase I/II trial (EXCLAIM)
  • EGFR EX20ins+ metastatic NSCLC with >=1 prior line of therapy, platinum-pretreated (n=114)
  • Mobocertinib 160 mg PO daily
Efficacy:
  • ORR: 28%, Disease control rate: 78% [69%-85%]
  • Median DoR: 17.5 mos [7.4-20.3 mos]
  • Median OS: 24.0 mos [14.6-28.8 mos]
Safety:
  • Grade >= 3 AEs: Diarrhea (22%)

J Clin Oncol. 2021;39:suppl 9014.

Ramalingam SS, et al. Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study

https://doi.org/10.1200/JCO.2021.39.15_suppl.9014

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More